APLS
Apellis Pharmaceuticals Inc
3.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -10.6% | -3.6% | +5.5% | +8.7% | -0.3% | -1.9% | -8.8% | +1.7% | +28.9% | +1.6% | +0.7% | |
| – | -10.7% | -3.8% | +5.9% | +6.0% | -3.0% | -5.4% | -7.8% | +3.8% | +31.1% | +2.4% | +1.3% | |
| – | -26.6% | -22.4% | -6.9% | +10.1% | +10.2% | +3.6% | -12.9% | +3.6% | +29.0% | -2.4% | -13.0% | |
| – | -25.6% | -24.3% | -7.2% | +12.5% | +7.8% | +4.9% | -13.9% | +3.6% | +29.0% | -2.4% | -13.0% | |
| – | +45.7% | +10.4% | +29.7% | +15.3% | -8.1% | -4.3% | -10.1% | -6.2% | +54.7% | +3.3% | +21.5% | |
| – | +7.9% | +27.0% | +10.2% | +0.6% | -25.4% | -31.9% | 0.0% | +46.7% | +1.5% | +16.1% | -7.8% | |
| – | +2.8% | +1.4% | -4.9% | +13.3% | +3.8% | -1.2% | -2.0% | +3.4% | -1.1% | +7.2% | -5.3% | |
| – | +6.2% | +33.4% | -13.0% | -21.4% | +13.1% | -3.0% | -3.8% | +12.5% | +39.3% | +15.8% | -12.4% | |
| – | -1.9% | +12.2% | +1,294.2% | -93.1% | +9.3% | -0.6% | +2.8% | +6.8% | +1,256.0% | +0.1% | 0.0% | |
| – | -33.8% | +106.2% | -28.6% | +42.9% | +11.7% | -9.7% | +43.3% | -1.9% | -28.8% | +47.1% | -13.6% | |
| – | +0.1% | +0.1% | +0.1% | +391.0% | -1.1% | +0.1% | +0.1% | +0.1% | -20.5% | +0.2% | +0.2% | |
| – | -32.8% | -16.3% | +37.1% | -0.9% | -10.3% | -3.6% | -28.1% | -4.8% | +156.7% | -7.7% | +12.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.8% | +0.8% | +1.4% | +0.8% | +0.0% | +0.0% | +1.3% | +0.5% | +0.0% | +0.0% | +0.0% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.